Voyager Therapeutics reports Q3 net income $17.6M; Pfizer exercises TRACER capsid option

Voyager Therapeutics, Inc.

2022-Q3 EPS reported -$0.59 revenue$42,457,000

Collaboration revenue $41.1M (vs $1.5M YoY) driven by $40M Pfizer option exercise recognition.
Net income $17.6M vs loss of $25.1M; cash $131.6M plus $10M Pfizer payment received in October.
Pfizer exercised option to license novel capsid; $10M payment, up to $290M in milestones plus tiered royalties.
Pipeline: lead development candidates for GBA1, SOD1, anti-tau programs expected Q4 2022 to H1 2023.
Novartis option decision on TRACER capsids for up to 5 targets expected by March 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.